Equities

Harbin Pharmaceutical Group Co Ltd

600664:SHH

Harbin Pharmaceutical Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)2.95
  • Today's Change0.02 / 0.68%
  • Shares traded18.28m
  • 1 Year change-4.22%
  • Beta0.6221
Data delayed at least 15 minutes, as of Mar 29 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Harbin Pharmaceutical Group Co is a China-based company mainly engaged in pharmaceutical research and development. The Company's main businesses are innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals, covering the business sectors of antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The Company’s main products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, Xingaizhonggai high calcium tablets, etc.

  • Revenue in CNY (TTM)15.31bn
  • Net income in CNY598.45m
  • Incorporated1991
  • Employees10.06k
  • Location
    Harbin Pharmaceutical Group Co LtdNo. 7 Qunli Avenue, Daoli DistrictHAERBIN 150070ChinaCHN
  • Phone+86 45 151870077
  • Fax+86 45 151870077
  • Websitehttps://www.hayao.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shenzhen Chipscreen Biosciences Co Ltd542.86m167.78m6.91bn1.05k40.003.96--12.740.42030.42031.344.250.18421.904.80519,478.904.241.494.871.7190.5394.9823.037.503.03--0.36840.0023.1136.83-20.37-6.2024.68--
Chengdu Easton Biopharmaceuticals Co Ltd1.12bn244.74m6.97bn1.32k28.472.71--6.212.042.049.3521.410.3611.648.03848,603.907.8710.139.6012.3979.1286.8721.8018.642.91--0.076321.8714.4319.706.0630.8171.28--
Beijing Foyou Pharma Co Ltd3.34bn486.79m7.13bn3.26k14.642.12--2.141.011.016.956.990.78173.529.061,024,990.0011.46--14.81--66.30--14.66--3.01--0.0374--14.18--39.43------
Shenzhen Lifotronic Technology Co Ltd1.15bn328.58m7.38bn1.48k22.424.11--6.440.7690.7692.684.200.55192.838.80773,611.6015.7813.8220.1316.3364.6461.0128.5826.102.88--0.119441.5116.5528.7830.6632.27-7.91--
Harbin Pharmaceutical Group Co., Ltd.15.31bn598.45m7.39bn10.06k11.991.59--0.48250.24440.24446.271.841.146.453.401,521,468.004.910.640313.711.4925.5023.844.320.66821.0322.940.39590.007.862.8225.142.67-2.55--
JiangSu WuZhong Pharmactcl Devlpm Co Ltd2.15bn-18.42m7.56bn1.01k--4.09--3.52-0.0247-0.02472.972.590.531614.602.062,130,038.00-0.5042-3.88-1.01-6.6826.6430.38-0.9485-8.281.280.62430.492--14.12-7.30-435.43---31.67--
Vcanbio Cell & Gene Engineering Corp Ltd1.58bn130.95m7.61bn2.33k58.102.06--4.810.27980.27983.387.900.29692.032.76677,972.802.301.043.251.4966.5667.187.753.521.53--0.03090.001.273.32-27.2661.242.26--
Youcare Pharmaceutical Group Co Ltd4.00bn151.79m7.67bn3.19k50.552.13--1.920.33730.33738.887.990.68052.183.961,253,963.002.658.253.9415.0759.0763.813.898.511.30--0.179453.50-8.5310.96-38.5715.7039.08--
Guangxi Wuzhou Zhongheng Group Co Ltd2.99bn53.69m7.87bn3.36k143.851.19--2.630.01590.01590.87011.920.25321.774.73891,014.10-0.18993.69-0.29695.2557.7077.66-0.750110.682.58--0.181942.74-14.175.79-74.25-33.442.52-30.12
Data as of Mar 29 2024. Currency figures normalised to Harbin Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

1.83%Per cent of shares held by top holders
HolderShares% Held
Fullgoal Fund Management Co., Ltd.as of 30 Jun 202331.39m1.25%
The Vanguard Group, Inc.as of 29 Feb 20244.16m0.17%
China Merchants Fund Management Co., Ltd.as of 30 Jun 20232.41m0.10%
Maxwealth Fund Management Co., Ltd.as of 30 Jun 20231.88m0.08%
Broad Fund Management Co. Ltd.as of 30 Jun 20231.63m0.07%
Dimensional Fund Advisors LPas of 07 Mar 20241.28m0.05%
Gfund Management Co., Ltd.as of 30 Jun 20231.10m0.04%
Orient Fund Management Co., Ltd.as of 30 Jun 20231.00m0.04%
Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 2023736.60k0.03%
China Fund Management Co., Ltd.as of 30 Jun 2023564.00k0.02%
More ▼
Data from 30 Jun 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.